StemCellReportsArticleStemCellFactor-BasedIdentiﬁcationandFunctionalPropertiesofInVitro-SelectedSubpopulationsofMalignantMesotheliomaCellsWalterBlum,1,*La´szlo´Pecze,1EmanuelaFelley-Bosco,2LicunWu,3MarcdePerrot,3andBeatSchwaller11UnitofAnatomy,DepartmentofMedicine,UniversityofFribourg,RouteAlbert-Gockel1,1700Fribourg,Switzerland2LaboratoryofMolecularOncology,Lungen-undThoraxonkologieZentrum,UniversityHospitalZu¨rich,Sternwartstrasse14,8091Zu¨rich,Switzerland3LatnerThoracicSurgeryResearchLaboratories,DivisionofThoracicSurgery,TorontoGeneralHospital,UniversityHealthNetwork,UniversityofToronto,Toronto,ONM5G2C4,Canada*Correspondence:walter-vincent.blum@unifr.chhttp://dx.doi.org/10.1016/j.stemcr.2017.02.005SUMMARYMalignantmesothelioma(MM)isanaggressiveneoplasmcharacterizedbyapoorpatientsurvivalrate,becauseofrapidtumorrecurrencefollowingﬁrst-linetherapy.Cancerstemcells(CSCs)areassumedtoberesponsibleforinitiatingtumorigenesisanddrivingrelapseaftertherapeuticinterventions.CSC-enrichedMMcellsubpopulationswereidentiﬁedbyanOCT4/SOX2reporterapproachandwerecharacterizedby(1)increasedresistancetocisplatin,(2)increasedsensitivitytowardtheFAKinhibitorVS-6063invitro,and(3)ahighertumor-initiatingcapacityinvivoinorthotopicxenograftandallograftmousemodels.OverexpressionofNF2(neuroﬁbromatosis2,merlin),atumorsuppressoroftenmutatedorlostinMM,didnotaffectproliferationandviabilityofCSC-enrichedMMpopulationsbutrobustlydecreasedtheviabilityofreporter-negativecells.Incontrast,downregulationofcalretininstronglydecreasedproliferationandviabilityofbothpopulations.Insummary,wehaveenrichedandcharacterizedasmallMMcellsubpopulationthatbearstheexpectedCSCcharacteristics.INTRODUCTIONMalignantmesothelioma(MM)isahighlyaggressiveneoplasmmostoftenlinkedtoexposuretoasbestosﬁbers,whichinducechronicinﬂammationandperpetualtissuerepairbythesurroundingmesothelialcells.Chronichy-per-proliferationleadstoaseriesofgeneticandepigeneticmodiﬁcationsofthesecellsgraduallydevelopingintoma-lignantcancercellsandtumorformation(Staheletal.,2009).Therapygenerallycomprisesacombinationchemo-therapyconsistingofcisplatin(cis-Pt)andpemetrexed,attimesaccompaniedbyradiotherapyand/ortumorremovalbysurgery(Choetal.,2014).Thelowsuccessrateoftreat-mentsislikelycausedbyasubpopulationoftumorcellscharacterizedbyhighresistancetochemotherapyandahightumor-formingpotentialleadingtorapidrecurrence,theso-calledcancerstemcells(CSCs).Currentlynouni-versalmarkersexistforunambiguouslyidentifyingCSCsinMMorothercancertypes,possiblylinkedtothedy-namicandheterogeneouspropertiesofCSCs(Akrapetal.,2016).VariousassayshavebeendescribedtoenrichCSC-containingtumorcellsubpopulations:ﬂuorescence-activatedcellsorting(FACS)ofputativeCSCs,some-timesalsocalledtumor-initiatingcells(TICs),reliesmostlyonexpressionofcellsurfacemarkers(CD133,CD44,CD24;Klonischetal.,2008;orEpCAM;VisvaderandLin-deman,2008)orondye-exclusionassaysbasedontheelevatedexpressionofABCtransporterfamilymembers,e.g.,ABCG2(Hirschmann-Jaxetal.,2004).Alternatively,increasedaldehydedehydrogenase(ALDH1)activitychar-acterizesasubpopulationofcancercellswithCSCproper-ties(D’AngeloandWicha,2010),alsoinhumanMMcelllines(Shapiroetal.,2014).Thecurrentlymostcomprehen-sivecharacterizationofCSCsubpopulationshasallowedtheidentiﬁcationofahierarchicalorganization,whereCSCsubpopulationsdynamicallychangebetweenvariousdifferentiationstates(clusters)(Akrapetal.,2016).Eachclusterischaracterizedbyaseriesofgenes;CSCsexpressingtypical(normal)pluripotencystemcellmarkergenessuchasSOX2,NANOG,andOCT4(alsonamedPOU5F1)werefoundattheapexofthehierarchy,followedbypopulationsofonetoseveraltypesofprogenitorcellpopulationsexpressinggenessuchasALDH1andABCG2.Thus,CSC-enrichmentmethodsbasedonstemcellmarkerexpressionincludingSOX2andOCT4havebeenparticularlysuccess-fulinselectingtumorcellswith(1)thehightumor-formingpotentialinvivo,(2)theparticulargrowthpropertiesincludingself-renewalandasymmetriccelldivision,(3)theincreasedchemoresistance,and(4)theaggressivenessshowninothercancertypes(Gangemietal.,2009;Tangetal.,2015).TheconceptthatCSCswithinatumormassmightrepresentimportanttargetsfortherapyisnowacceptedfornearlyallcancertypes(Valentetal.,2012).Here,weidentiﬁedandcharacterizedMMcellsubpopu-lationsinvitrobasedontheirincreasedendogenousexpressionofSOX2andOCT4drivingareporter(EGFP)(Hottaetal.,2009;Tangetal.,2015).Wedemonstratethesecellstohavedifferentpropertieswithrespecttochemore-sistance,andthattheproportionofthesecellsappearstobedeterminedintrinsically,alsoinvolvingasymmetriccelldivision.Moreover,overexpressionofthetumorsuppressorNF2causedanalmostcompleteblockofcellStemCellReportsjVol.8j1005–1017jApril11,2017jª2017TheAuthor(s).1005ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/4.0/).proliferationinnon-enrichedCSCcells,whilehighSOX2/OCT4-expressingcellsselectedbythereporterapproachwerebarelyaffectedbyforcedNF2expression.InjectionoftheEGFP(+)cellsresultedinanincreasedfrequency,number,andsizeoftumorsinvivocomparedwithcellswithlowSOX2/OCT4expression.Theseresultsareindica-tiveofaCSC-enrichedpopulationinMMcelllinesofhu-manandmouseoriginlikelyrelevantfortumorrelapse.RESULTSIdentiﬁcationandInitialCharacterizationofHighSOX2/OCT4-ExpressingHumanCSC-EnrichedMMCellsToidentifyputativeCSCsinMM,wereliedonatoolinitiallydevelopedforstemcellbiology(Hottaetal.,2009).Inthislentivirus-basedapproach,MMcellsofhu-manandmouseoriginwereinfectedwithaconstructthatcontainsSOX2-andOCT4-bindingsitesinthepromoterre-gion,followedbyanexpressioncassettecodingforEGFPandanIRESconnectingtoapuromycin-resistancecassette(Figure1A).Thus,cellsexpressinghighlevelsofSOX2/OCT4canbeidentiﬁedbyEGFPexpressionand,moreover,selected/isolatedbytheirpuromycinresistanceand/orbyFACS.TheoveralllentiviraltransductionefﬁciencyinMMcelllineswasassessedwithaconstitutiveNLS-mCherryconstruct(FiguresS1BandS1C).FACSanalysesre-vealedapproximately85%ofcellstoshowredﬂuorescence;anoverlayofbrightﬁeldandﬂuorescenceimagesfromtransducedZL55andRN5MMcellsandvisualinspectionindicatedthatthetransductionefﬁciencywaslikelyevenhigher,i.e.,intheorderof>90%(FigureS1B).Inthepopu-lationofinfectedZL55cellsnamedZL55-SOcells,weobservedapproximately5%ofEGFP-expressing(EGFP(+))cells(Figure1B).AsimilarpercentageofhighSOX2-andOCT4-expressingEGFP(+)cells(ZL55z4%;FigureS1A3)wasobtainedwiththeSORE6reporterconstructpreviouslyFigure1.AnEGFPReporter-BasedandPu-romycin-SelectedSubpopulationofZL55CellsShowsHigherTranscriptLevelsofCSC-AssociatedGenes(A)SchematicrepresentationofthepL-SIN-EOS-S(4+)-EiPlentiviral(LV)constructwithOCT4(blue)andSOX2(orange)bindingsites.BindingofOCT4andSOX2initiatesexpressionofEGFPandPuroR.(B)AsmallpercentageofEGFP(+)cellsispresentinLV-transducedZL55cells(leftpanel,brightﬁeldimage;rightpanel,ﬂuo-rescenceimage).(C)FACSanalysisrevealsanEGFP(+)sub-populationofaround5%(C2);withthesamegatingonly0.05%ofnon-infectedZL55cellsarecounted(C1).(D)Directlyafterpuromycinselectionstrin-gentFACSanalysisofZL55-SO-P2cellsiden-tiﬁes78.6%ofcellsasEGFP(+).(E)PuroRselectionresultsinavisibly100%positiveEGFP(+)ZL55-SO-P2subpopulation(right);leftimage:brightﬁeldimageofthesamecells.(F)qRT-PCRrevealsa4.5-foldincreaseforSOX2expressioninZL55-SO-P2andZL55-SO-P10cells(selectedwith2or10mg/mLofpuromycin,respectively)comparedwiththenon-selectedZL55-SOcells.OCT4levelsareincreased1.9-foldin-P2andnearly6-foldinthe-P10cells.AsigniﬁcantincreaseintheexpressionofABCG2aswellasCSF1Risdetected.Statisticalcomparisonswereper-formedusingaone-wayANOVA(*p<0.05)fromthreeindependentexperiments;errorbarsrepresentSD.SeealsoFigureS1.1006StemCellReportsjVol.8j1005–1017jApril11,2017usedinbreastcancercells(Tangetal.,2015).Thisper-centagelieswithinasimilarrangetothatobservedfortheZL55sidepopulation(2%SPcells,Freietal.,2011)orALDEFLUOR-positive(+)MM87cells(3.8%;Shapiroetal.,2014).QuantitativeanalysesbyFACSshowed4.86%ofZL55-SOcellstoexpresssufﬁcientlyhighlevelsofSOX2andOCT4todriveEGFPexpression(Figure1C).ZL55-SOcellssubjectedtopuromycin(2mg/mL)selectionfor7daysrevealedthesurvivingcellpopulationtoshowvari-ableEGFPexpressionandwerenamedZL55-SO-P2.InordertoexcludelikelyEGFP-negativeorlowEGFP-expressingcellsinthequantitativeFACSanalyses,basedonthestrin-gentFACSsettings,78.6%ofZL55-SO-P2cellsfulﬁlledthecriteriatobeunmistakablyidentiﬁedasEGFP(+)cells(Fig-ure1D);yet,byeye,essentiallyallcellsappearedtoemitgreenﬂuorescence(Figure1E).Inaddition,wegeneratedZL55-SO-P10cells,wherethepuromycinconcentrationwasaugmentedto10mg/mLaimedatselectingcellswiththehighestlevelsofSOX2andOCT4.Expressionlevels(mRNA)ofSOX2,OCT4,aswellaspreviouslyproposedMMCSCmarkersincludingABCG2andCSF1R,allimpli-catedinmesotheliomachemoresistance,wereconsiderablyincreased(onaverage3-to5-fold)inpuromycin-selectedZL55-SOcells(Figure1F).Thelargestincreasefrom-P2to-P10cellswasobservedforOCT4(Figure1F).ExperimentswerecarriedoutwithFACS-sortedcells,whichweresepa-ratedbasedonlyontheirEGFPﬂuorescence.DetailsforthesortingareprovidedinFigureS2A.TheidenticalapproachwasalsousedtoobtainsortedRN5cells(Fig-ureS2B).WescreenedthesortedcellsforALDH1A1,KLF4,andc-MYC,whichwereallincreasedinZL55-SOhighcells(FiguresS1DandS1E).InthesortedmurineRN5-SOhighcells,besidesSox2andOct4,thestemcellmarkerNanogwasalsosigniﬁcantlyincreased(FigureS1F).AhallmarkforputativeMMandothertumortype-derivedCSCsistheirincreasedresistancetowardchemotherapeuticdrugsincludingcis-Pt,asalsoreportedpreviouslyforovariancan-cer-derivedCSCs(Wiechertetal.,2016).ZL55-SOandZL55-SO-P2cellsweretreatedwithcis-Ptconcentrationsrangingfrom0.625to10mM,andcellsurvivalwasassessed5dayslater(Figure2A,leftpanel).Halfmaximalinhibitoryconcentration(IC50)valueswere0.92mMforZL55-SOand2.13mMforZL55-SO-P2cells,indicatingthattheEGFP(+)cellsdisplayedhigherchemoresistance,i.e.,highersurvivalthanthenon-selectedZL55-SOcells.WhileZL55-SO-P2cellswerealmostcompletelyresistantto1.25mMcis-Ptasshownbynearlyidenticalgrowthcurvesofcis-Pt-exposedanduntreatedcells,thegrowth/survivalofZL55-SOcellswasconsiderablyimpairedundertheseconditions(Fig-ure2C).Ofnote,inZL55-SOcells,thecellssurvivingthecis-PttreatmentweretoalargeextentEGFP(+)cells(Fig-ure2D)presentatabout5%inthenon-selectedZL55-SOcells(Figures1Band1C).Also,thesortedZL55-SOlowandZL55-SOhighcellswereexposedtocis-PtandIC50valuesweredetermined(Figures2Aand2B).Theincreaseinsur-vivalofZL55-SOhighcellscomparedwithZL55-SOlowcellsinthepresenceofcis-Ptwasqualitativelysimilartothatinthepuromycin-selectedZL55-SO-P2versusZL55-SOcells(Figure2A).Withrespecttotheincreasedresistance,theratioofIC50valuesfortheEGFP(+)-sortedcells(2.7-fold)wasslightlyhigherthanforthe-SO-P2versus-SOcells(1.9-fold);thesmallerdifferenceinthepuromycin-selectedcellslikelybeingduetothepresenceofapproximately5%ofEGFP(+)cellsintheparental(unsorted)-SOcellpopula-tion.Sortedcellswerealsoexposedto5-ﬂuorouracyl(5-FU)andtotheFAKinhibitorVS-6063,alsoknownasdefactinib.IC50valuesaresummarizedinFigure2B.Ofnote,nodiffer-encesweredetectedinZL55-SOlowandZL55-SOhighcellswithrespecttotheir5-FUsensitivity.InlinewithpreviousobservationsthatFAKsignalingisincreasedandfunction-allyrelevantinputativeCSCs(Shapiroetal.,2014),ZL55-SOhighcellsweremoresusceptibletowardtheFAKinhibitorthantheZL55-SOlowcells(Figures2Aand2B).SOX2/OCT4-ExpressingCSC-EnrichedMMCellsShowStemCellPropertiesInVitroAnessentialpropertyofstemcellsisasymmetriccelldivision,i.e.,theabilitytogeneratetwodaughtercellswithnon-identicalproperties.WehypothesizedthatinZL55-SO-P2EGFP(+)cellsnotcontinuouslysubjectedtopuromycinselectionorinFACS-sortedZL55-SOhighcells,afractionofcellswouldeventuallyloseEGFPexpression,possiblyresultingfromasymmetriccelldivisionand/oradynamicswitchinCSCdifferentiationstate(MovieS1).While1dayafterpuromycinremovalessentiallyallcellswereEGFP(+),atlatertimepoints(days6,71,and80),ﬁrstindividualEGFP( )cellsandatlaterstagesentirecellclustersofEGFP( )cellswereobserved(Figure3AandMovieS2).Asymmetriccelldivisionsweredocumentedbytime-lapsevideos,wheremitosisofanEGFP(+)cellre-sultedinagreenandanon-greendaughtercell(MovieS1).AdecreaseofEGFP(+)cellsby13%wasobservedatday80(10passages)(Figure3BandMovieS2),andgreencellsdecreasedevenmoreafterlong-termculturinginvitro(datanotshown).Theiradvancementindifferenti-ationfromEGFP(+)toEGFP( )cellswasconﬁrmedbytheirsubsequentincreasedNF2susceptibility(MovieS4).Ofnote,withinthepopulationofEGFP(+)cells,asecondpopulationofcellsappearedwithaweakergreenﬂuores-cenceintensity,closetothegatingboundariesseparatingEGFP(+)andEGFP( )cells(Figure3B).WeconcludethatEGFPexpressionisnotbasedonanall-or-nonemecha-nism,butitexistsratherasacontinuumofcellswithdifferentSOX2/OCT4-basedreportersasshownbythehet-erogeneousEGFPlevelspossiblyresultingfromaswitchinCSCdifferentiationstate.StemCellReportsjVol.8j1005–1017jApril11,20171007SOX2/OCT4-ExpressingCSC-EnrichedMMCellsArePresentinCellLinesDerivedfromAllHumanMMHistotypesandAlsoinMurineRN5MMCellsPatientswithsarcomatoidandbiphasicMMhaveapoorerprognosisthanpatientsdiagnosedwithanepithelioidMM(Bille´etal.,2016).Thus,wesetouttoinvestigatewhetherhighSOX2/OCT4-expressingcellswerepresentincelllinesderivedfromalldifferentMMhistotypesandtodeterminetheproportionofEGFP(+)cells.EGFP(+)cellpopulationsweredetectedinZL55(epithelioid),MSTO-211H,SPC111(biphasic),andmurineRN5(sarcomatoid)cells;theirfrac-tionsrangedfrom4.8%to7.8%(Table1).Thus,inallthreehistotype-derivedMMcelllines,EGFP(+),CSC-enrichedcellpopulationswereidentiﬁed.MurineEGFP(+)RN5cellswereusedinasyngeneicorthotopicinvivomousemodelaimedatdemonstratingthatthedecreaseofEGFP(+)cellsobservedincultureisnotanartifactofinvitrocellcultureconditionsand/orspeciﬁcforacertainMMcellline.SortedRN5-SOhighcellswereusedinaninvivoallograftC57Bl/6Jmousemodel.Intraperitoneal(i.p.)injectionofthesecellsresultedintumornodulesafter8weeks;stainingofﬁxedtumorswithapan-cytokeratin(CK)antibodyallowedidentiﬁcationofthetumorcells,furtherconﬁrmedbydou-blestainingforEGFP(Figure3C).ThetumorcontainedpatchesofcellswithstrongEGFPexpression,butalsore-gionswithweakorabsentexpression,althoughthesecellswereclearlyCKpositive,i.e.,tumorcells.ThisindicatesthatafractionofEGFP(+)tumorcellshadlostSOX2/OCT4-drivenreporterexpressionovertimeinvivo.Furthermore,RN5-SOhigh-sortedcellsweretransducedwithNLS-mCherryandinjected(i.p.)intomice.Tumorswerecollectedafter8weeksandisolatedtumorcellswereculturedinvitroforanalysis.AmongtheNLS-mCherry-labeledRN5MMcells,afractionofEGFP( )cellswasde-tected(markedbyarrows;Figure3D).Inaddition,theseNLS-mCherry-transducedRN5-SOhighcellswereculturedinvitroforanadditional57days.CellswereanalyzedweeklybyFACS;thefractionofEGFP( )cellsincreasedFigure2.HigherResistanceofZL55-SOhighEGFP(+)CellsTowardcis-Ptand5-FUandaLowerOneTowardVS-6063(AandB)IncreasedviabilityofZL55-SO-P2versusZL55-SOcellsexposedtocis-Pt(leftpanel)(A).FromthecurvesderivedfromsortedZL55-SOlowandZL55-SOhighcells(rightthreepanels),IC50valuesforcis-Pt,5-FU,andVS-6063werecalculatedfromthreeindependentexperimentsandareshownin(B).***p<0.001;one-wayANOVA;n.s.,notsigniﬁcant.ZL55-SOhighcellsdisplayhighersusceptibilitytoVS-6063.(C)Real-timegrowthcurvesshowthestrongeffectofcis-Pt(1.25mM)onZL55-SOcellproliferation/survival,whileZL55-SO-P2cellsarealmostcompletelyresistant.Onerepresentativeexperimentfromthreeindependentexperiments.(D)Brightﬁeldandﬂuorescenceimagesshowingtheeffectofcis-PtonZL55-SOcells;thefractionofEGFP(+)cellsisincreasedaftercis-Ptexposure(rightpanels).1008StemCellReportsjVol.8j1005–1017jApril11,2017Figure3.Time-DependentDecreaseinEGFPExpressioninInitially100%EGFP(+)CellsIndicatesGradualLossofStemnessObservedInVitroandInVivo(A)ExampleofEGFP(+)andEGFP( )ZL55-SOcellsinacellculturedishinitiallyplatedwithFACS-sortedZL55-SOhighcells.At80daysinvitromanynon-greenEGFP( )cellsareobserved,oftenarrangedinclusters(markedbyyellowdottedlines)andEGFP(+)(examplesmarkedbyreddottedlines).(B)DecreaseofthefractionofEGFP(+)cellsstartingfromsortedZL55-SOhighcells(initially78.6%EGFP(+)cells)to68.7%afterculturingwithoutpuromycinselectionfor35days(tenpassages).NotetheappearanceofadistinctpopulationofcellswithlowerEGFPﬂuorescence(arrow).(C)TumortissuederivedfromamouseinjectedwithRN5-SOhighcellsfor8weeksinvivo.Inthetumormassidentiﬁedbypan-cytokeratin(CK)immunohistochemistry(redﬂuorescence),clustersofcellswithweak-to-noneEGFPstaining(greenﬂuorescentimage;left)areseen.StainingwithDAPI(blue)allowsbetteridentiﬁcationofindividualcells.Inthemergedimage,thepresenceofclustersofyellowcells(co-localizationofCKandEGFP),butalsoofcellswithoutEGFP(CKonly)demonstrateslossofEGFPexpressionovertimeinvivo.(D)RN5-SOhighcellsadditionallyexpressingNLS-mCherry(redﬂuorescentnuclei)formedtumorsinvivoasdemonstratedafter8weeks.Tumor-derivedcellswerecultivatedinvitroandrevealedthatafractionofNLS-mCherry(+)cellshadlostEGFPexpression(cellsmarkedbyarrows).Inthemergedimagethesecellsappearasredonly.(legendcontinuedonnextpage)StemCellReportsjVol.8j1005–1017jApril11,20171009from0.4%to22.2%after57days,whilethefractionofNLS-mCherry( )cellsonlydecreasedby0.8%inthesametimeperiod(Figure3E).Anoverlayofthegreenandredcellpopulationspresentincellculturesafter57daysinvitrorevealedaleftshiftofthegreencellstowardlowerﬂuorescence(increaseinEGFP( )cells),whileatthesametimetheclusterofredcellsdidnotmove(Figure3E).ThisindicatesaselectivedecreaseofEGFP(+)cellsovertime,i.e.,SOX2/OCT4levelshaddroppedbelowthethresholdtomaintainEGFPexpression.TumorGrowthofZL55-SOhighCellsInVivoStronglyIndicatesCSCPropertiesThegrowthofFACS-sortedZL55-SOlowandZL55-SOhighcellswasinvestigatedinvivoinanorthotopicxeno-graftmousemodel.Non-obesediabetic(NOD)/severecombinedimmunodeﬁciency(SCID)gammamicewereinjectedi.p.with100,000ofeithersortedZL55-SOloworZL55-SOhighcellsandtheformationoftumornoduleswasanalyzed5weeksafterinjection.Allmiceexposedtoeithercellsubpopulationshowedmacroscopictumorformationsonboththeparietalandvisceralpartofthetunicaserosa(Figure4A).Wemeasuredsemi-quanti-tativelytherelativesurfaceareacoveredbytumortis-sue;aclearlylargersurfaceareacoveredbyvisuallydiscernibletumornodulesafterinjectionofZL55-SOhighcellswasobserved(Figure4B).InsomecasesnearlytheentireparietaltunicaserosaofmiceinjectedwithZL55-SOhighcellswascoveredwithtumornodules,buttoalesserextentalsothevisceraltunicaserosaofdifferentorganswascovered(Figure4A).Thesemi-quantitativeanalysesshowedthatthetumor-initiatingcapacityofZL55-SOhighEGFP(+)cellswasclearlyhigherthanthatofZL55-SOlowEGFP( )cells.HistologicalanalysesofselectedZL55-SOhightumornodulesshowedirregularlyformedboundariesbetweenlivertissueandtumormass,indicativeofahighlyinvasivetumor(Figure4C).CharacteristicsofRN5-SOhighTumorCellGrowthInVivoAreDifferentfromtheOneafterInjectionwithRN5-SOlowCellsAlimiteddilutionassaywascarriedout,wheredifferentamountsofFACS-sortedmurineMMcells(RN5-SOhighandRN5-SOlow;5,000,50,000,and500,000cellspermouse)wereinjectedi.p.insyngeneicC57Bl/6Jmice.Atthreetimepoints13,11,and8weekspostinjection,micewiththelargestinitialloadanalyzedaftertheshortestperiodwerekilledandthetumorload/tumorsizewasinvestigatedsemi-quantitatively,ﬁrstatthemacroscopiclevelandtheninmoredetailonhistologicalsections(Fig-ure5).InjectionofEGFP( )RN5-SOlowcellsresultedintheformationofmacroscopicallydiscernabletumorsin1of12mice(8.3%);thetumorlocalizationwasintramuscular(Figure5C).Moretumors(in6of12mice;50%)weredetectedafterinjectionofRN5-SOhighcells;anexampleofanexternallyvisibletumorofRN5-SOhighcellsisshowninFigure5B.HistologicalanalysesrevealedthatRN5-SOhigh-derivedtumorsoftenlocalizedwithinthesub-cutaneousconnectivetissue,inintramuscularregionsoftheabdominalwall,butalsoonthekidneycapsule(Fig-ures5D–5G).Differenttissuesamplescontainingsmalltu-mormassesfrommiceinjectedwitheitherRN5-SOhighandRN5-SOlowcellswerehistologicallyexamined.IntheRN5-SOlowgroup,tumorswereidentiﬁedin4of12(33%)miceandclearlymore(9of12mice;75%)inmiceinjectedwithRN5-SOhighcells(Figure5A).ThetumorincidenceinRN5-SOhigh-injectedmicewashigheratallthreedosesoftumorcellstested(Figure5A).Thecalculatedtumor-initiatingfre-quencyusingtheELDAsoftware(HuandSmyth,2009)forRN5-SOhighcellswasclearlyhigherthanforRN5-SOlowcells(ratioRN5-SOhigh/RN5-SOlow,17.4;p=0.0063).Thus,alsoinvivo,EGFP(+)RN5-SOhighcellsfulﬁllthecriteriaofCSC-enrichedcellsshownbytheirincreasedtu-mor-initiatingfrequency.IncreasedInVitroSelf-RenewalPropertiesofRN5-SOhighandZL55-SOhighCellsComparedwiththeCorresponding-SOlowSubpopulationsOtherimportantCSCcharacteristicsincludeanaugmentedcapacityforself-renewalandalsoforanchorage-indepen-dentgrowthinvitro(Morata-Tarifaetal.,2016).Self-renewalwasassessedinZL55andRN5cellsbyalimitingdilutionassayasdescribedpreviously(Tangetal.,2015;Thiagarajanetal.,2015)usingsorted-SOlowand-SOhighcellsofbothcelltypes.Inbothcelllines,theself-renewalca-pacityofEGFP(+)cellswasclearlyincreased(FiguresS3A(E)Cellsshownin(D)weremaintainedincultureinvitroforanadditional57daysandanalyzedbyFACSforgreen(EGFP)andred(NLS-mCherry)ﬂuorescence.WhilethefractionofNLS-mCherry(+)cellsonlymarginallydecreasedfrom99.8%to99.0%,thefractionofEGFP(+)cellsdecreasedfrom99.6%to77.8%.NotetheleftshiftofthepopulationofEGFP(+)cells:bluecloudatt1;redcloudatt57.SeealsoFigureS2.Table1.PercentageofEGFP(+)CellPopulationsinHumanandMouseMMCellLinesCellLineOrigin/Characterization%GFP(+)CellsZL55human/epithelioid4.8SPC111human/biphasic6.2MSTO-211Hhuman/biphasic6.1RN5murine/sarcomatoid7.81010StemCellReportsjVol.8j1005–1017jApril11,2017andS3B).ExamplesofEGFP( )andEGFP(+)RN5tumorspheresinitiatedfrom10cells/wellandmaintainedincul-turefor10daysareshowninFiguresS3CandS3D,respec-tively;thelargersizeofEGFP(+)tumorsphereswasevident.Inaddition,theanchorage-independentgrowthinsoftagarwasinvestigatedinthesamecelllines.TheaveragecolonysizeofEGFP(+)RN5-SOhighcellsafter2weeks(FigureS3E)wasconsiderablylargerthanthesizeofthecorrespondingEGFP( )RN5-SOlowcolonies(FigureS3F).Assumingasphericalshapeofthecolonies,basedontheareasofthecol-oniesdepictedinFiguresS3EandS3F,theradiusofaspherewascalculated.TheaverageradiuswassigniﬁcantlylargerinRN5-SOhighcellsthanintheRN5-SOlowcells(FigureS3H).ThedifferencesinradiiweresmallerbetweenEGFP( )andEGFP(+)ZL55cellcolonies;however,radiiofZL55-SOhighcellcolonieswerestillsigniﬁcantlylargerthantheonesfromEGFP( )cells(FigureS3G).DecreasedSusceptibilityofEGFP(+)ZL55CellstoAsbestos-InducedAcuteCytotoxicity,butUnalteredCellMobilityInVitroCSCsareknowntoshowhigherresistancetoexposuretocytotoxicagents(Vidaletal.,2013),possiblylinkedtotheirlowerproliferationrates,whileincreasedspreadingoftumorcellstositesdistantfromtheprimarytumorareassociatedwithaugmentedinvasivenessandincreasedmetastaticpotential(Anjomshoaaetal.,2009).ZL55-SO-P2EGFP(+)cellsweresigniﬁcantlymoreresistanttowardcrocidolite-inducedacutecytotoxicity(5mg/cm2ofcrocidolitefor96hr)thanEGFP( )cells(Figure6A).At96hrtheMTTsignalofZL55-SO-P2crocidolite-treatedcellswasonlyslightlylowerthanincontrolZL55-SO-P2cells,indicatinganalmostcompleteprotectionofEGFP(+)cells.Real-timegrowthcurvesofcontrolZL55-SOandZL55-SO-P2cellsdidnotreveallargedifferencesintheproliferationratesofthetwocellpopulations(Figures6Cand6D).TheMTTsignalat120hrpost-platingforEGFP( )ZL55-SOlowcellswasslightlylargerthanforEGFP(+)ZL55-SOhighcells,inlinewithslowergrowthofCSCs(datanotshown).Yetina2Dscratchassay,thewoundclosuretimewasindistinguishable(datanotshown).Amoredetailedanalysisofthemobilityofindivi-dualcellspreferentiallytowardthecell-devoidareashowedafastercellmovementofbothcellgroupsdirectlyfollowingthescratchandlastingforabout2hr,followedbyaconstantdisplacementofapproximately2mm/5minforthenext16hr(FigureS4C).MobilityofZL55-SOcellsgrownatlowconﬂuence,i.e.,allowingfornon-directedmovementwasalsonotdifferentbetweenEGFP(+)andEGFP( )cells(Fig-ureS4C).Inaddition,weusedMSTO-211Hcells,anMMcelllinepronetoformspheroidswhengrownintheabsenceofserum,toanalyzethespheroidformationcapacity(Pasdaretal.,2015).MSTO-211H-SO-P2cellsconsistingofmostlyEGFP(+)cellsshowedqualitativelyalargernumberofspher-oids(datanotshown)thatwerealsobiggerthantheonesfromunsortedMSTO-211H-SOcells(FiguresS4AandS4B).Ofnote,spheroidsproducedfromunsortedMSTO-211H-SOcellscontaininginitially7%ofEGFP(+)cellsweremostlymadeupoftheEGFP(+)cellsubpopulation,sug-gestingthatmostlyEGFP(+)cellsshowthepropensityofformingspheroids(FigureS4A).SimilarSensitivityofEGFP(+)andEGFP( )MMCellstoCalretininDownregulation,butPronouncedDifferenceswithRespecttoEctopicExpressionoftheFunctionalTumorSuppressorNF2andtotheFAKInhibitorVS-6063AlthoughthepreciseroleofthepositiveMMmarkercalre-tinin(CALB2)iscurrentlyunknown,itsdownregulationFigure4.IncreasedTumorGrowthofHumanZL55-SOhighEGFP(+)CellsinNOD/SCIDGammaMice(A)ZL55-SOlowandZL55-SOhighcells(100,000/mouse)werein-jectedi.p.intoNOD/SCIDgammamice.MiceinjectedwithZL55-SOhighcellsshowanincreasednumber/densityoftumornodules,especiallyvisibleonthevisceralpleura(rightimages).(B)Thepercentageoftumornodulescoveringthesurfaceofthevisibleparietalandvisceralperitoneumis9.1%forZL55-SOlowcellsand27.8%forZL55-SOhighcells(***p<0.001;one-wayANOVA).Averageoffourtoﬁveanimalspergroup;errorbarsrepresentSD.(C)Tumormasseswerehistologicallyanalyzed;atumornoduleontheliversurfaceshowshighlyinvasiveedges(arrow).SeealsoFigureS3.StemCellReportsjVol.8j1005–1017jApril11,20171011inZL55cellsbyalentivirus-mediatedshorthairpinRNA(shRNA)approachleadstomassiveapoptosisandnecrosis,moststronglyinepithelioidMM(BlumandSchwaller,2013).Ofnote,calretininproteinlevelsweresimilarinZL55-SOandZL55-SO-P2cells(Figure6G)and,moreimportantly,downregulationwithshCALB2no.5,shCALB2no.7(BlumandSchwaller,2013),andveryefﬁ-cientlywithshCALB2no.84(targetingtheCALB230UTR)affectedthesurvivalofZL55-SOandZL55-SO-P2cellstoasimilarextent(Figure6B).Thus,unlikethesituationwiththeFAKinhibitorVS-4718thatpreferentiallyaffectsALDEFLUOR(+),CSC-enrichedMMcells(Shapiroetal.,2014),CALB2downregulationequallyaffectedprolifera-tionandviabilityofZL55EGFP(+)andEGFP( )cells.Theseresultsunderscorecalretininasaninterestingtargetfortheeliminationofcalretinin-positiveMMcellsirrespectiveoftheirstemness.GenesthataredownregulatedorlostinMMandarethoughttoactasadriverforMMformationincludeNF2(neuroﬁbromatosis2,merlin),CDKN2A,andBAP1(Xuetal.,2014).LossoffunctionalNF2resultingfrommuta-tionsisobservedin40%–50%ofhumanMPM(Bianchietal.,1995)and,moreover,lowNF2-expressingMPMcellsshowahighersensitivitytowardFAKinhibition-inducedgrowtharrest,whileNF2overexpressionresultsinanincreasedresistancetotheFAKinhibitorVS-4718thatpreferentiallyaffectsALDEFLUOR(+)CSC-enrichedcells(Shapiroetal.,2014).Thus,weinvestigatedhowoverex-pressionofhumanwild-typeNF2affectedproliferationand/orsurvivalofEGFP(+)andEGFP( )MMcells.Thepro-liferationofcontrolZL55-SOandZL55-SO-P2wasrathersimilar,aplateauwasreachedbetween70and80hrafterplating(Figures6Cand6D).OverexpressionofNF2(Figures6C–6F)selectivelyaffectedEGFP( )ZL55-SOcells,asshownbyanalmostcompletecellgrowtharrestandcelldeath(Figures6C–6F).NF2-overexpressingEGFP(+)ZL55cellsshowedthetypicalepithelioidmorphology,whileneighboringEGFP( )cellswerecharacterizedbyroundingupandcellprotrusionstypicalfordying(apoptotic/necrotic)cells(Figures6Eand6F;MoviesS3andS4).NF2upregulationonlymarginallyaffectedtheproliferationofEGFP(+)ZL55-SO-P2cells(Figure6D),andthecellFigure5.IncreasedTumor-InitiatingFre-quencyandMorphologicalAspectsofRN5-SOhighEGFP(+)Cell-DerivedTumorsinSyngeneicC57Bl/6JMiceRN5-SOlowandRN5-SOhighcellswereinjectedi.p.inC57Bl/6Jmiceatthreedoses(500,000,50,000,and5,000cells)andkilledafter8,11,and13weeks,respectively.(A)Fractionofmicewithtumorsfoundbymicroscopicanalyses.AtallinjecteddosesofRN5cellsandtimepoints,tumorincidenceishigherwithRN5-SOhighcells.Thetumor-initiatingfrequency(TIF)wascalculatedforbothgroups.(B–F)H&E-stainedsections.(B)TumorofRN5-SOhighcells(500,000cellsat8weeks);tumorcellsarelocatedsubcutaneouslyintheparietalwall.(C)Intramusculartumorintheabdominalwallofthesamemouse.(D)Inthesamegroup(500,000cellsat8weeks),tumorcellgrowthontheliversurface.(E)and(F)Intramusculartumorsinamouse(50,000RN5-SOhighcellsat8weeks).(G)Aparallelsectionoftheonepresentedin(F)showsaGoldnerstainingtobetteremphasizethemuscletissue(red)andtheconnectivetissue(green)inthetumormass.Arrowsin(F)and(G)indicatemuscleﬁbers.SeealsoFigureS3.1012StemCellReportsjVol.8j1005–1017jApril11,2017morphologywasunaltered(Figures6Eand6F).NearlyidenticalresultswereobtainedwithhumanMSTO-211H,SPC111,andZL5cells(FiguresS4E–S4J).Theslowandde-layedincreaseintheproliferationofZL55-SO-NF2cellswastheresultofthelowpercentage(5%)ofEGFP(+)cellspresentintheunselected(-SO)cells,sincenearlyallcellsweregreenat120hr(FigureS4F).AsimilareffectwasalsoseenwithmurineRN5cells.Thesmallermagni-tudeoftheeffectmightbelinkedtothefactthathuman,notmouseNF2,wasoverexpressedinthemousecells.Thus,inlinewithpreviousreportsdemonstratingthatNF2upregulationinMMcellsleadstogrowthinhibitionandapoptosis(Xiaoetal.,2005),NF2overexpressionblockedproliferationonlyin-SOcellsmostlyconsistingofEGFP( )cells,whilebarelyaffectingEGFP(+)cells.Thus,incontrasttotheEGFP( )cells,theCSC-enrichedpopulationderivedfromallMMhistotypeswasratherinsensitivetoNF2overexpression.Ontheotherhand,theFAKinhibitorVS-6063moreefﬁcientlydecreasedcellproliferationinZL55-SO-P2EGFP(+)cellscomparedwithZL55-SOcells(Figures2Aand2B).DISCUSSIONMMareexceptionallyresistanttotherapeuticinter-ventionssuchaschemotherapy,radiotherapy,surgery,andcombinationsthereof.Inmanyinstancestherapyresistanceislinkedtoaparticularmicroenvironment(KlemmandJoyce,2015)createdandmaintainedbythetumortissueand,moreover,bytheheterogeneityofthetu-morcellswithinthetumormass(Bedardetal.,2013).AsmallsubpopulationofcancercellswithstemcellfeaturestermedCSCs,orfunctionallydeﬁnedasTICs,isassumedtoplayacrucialroleinthedevelopmentofcancerandinpromotingitssustainedgrowthandtheinvasiveandFigure6.DecreasedSusceptibilityofEGFP(+)ZL55CellstoAsbestosToxicityandNF2Expression;EqualSensitivityofEGFP(+)andEGFP( )ZL55CellstoCalre-tininDownregulation(A)IncreasedresistanceofZL55-SO-P2cellsexposedto5mg/cm2ofcrocidolitefor96hrdeterminedbyanMTTassaycomparedwithZL55-SOcells(n=3inde-pendentexperiments,one-wayANOVA;***p<0.0005).(B–D)DownregulationofcalretinininZL55-SOandZL55-SO-P2cellsequallydecreasestheviabilityinbothcellpopulationsforthreedifferentshRNAtargetingCALB2(B)(n=3independentexperiments;one-wayANOVA;n.s.,notsigniﬁcant).Overexpressionofmerlin(NF2)inZL55-SO(C)andZL55-SO-P2cells(D)showsstrongproliferation-in-hibitingeffectsonthenon-sortedZL55-SOcells,butalmostnoeffectonZL55-SO-P2cells.Theinsetin(D)showsstrongupregu-lationoffull-lengthNF2(Mr=68kDa)us-ingLV-NF2.AllerrorbarsrepresentSD.(E)Live-cellimagingofZL55-SO3hrafterupregulationofNF2;notethepresenceofEGFP(+)andEGFP( )cellsintheZL55-SOcellpopulation.Themorphologyofgreenandnon-greencellsismostlyepithelioid.(F)Twenty-sevenhourspostinfection,theupregulationofNF2inducedstrongapoptosis/necrosisinnon-greencells(whitearrows)demonstratedbycellshrinkage,blebbing,andcelldebris.EGFP(+)cellsdonotshowstrikingmorphologicalchanges.(G)WesternblotanalysisshowingstrongdownregulationofCR(Mr=31kDa)byshRNACALB2no.5inZL55-SOandZL55-SO-P2cells.Atapproximately35kDa,thenitrocellulosemembranewascutandtheupperpartwasusedforGAPDHdetection(lowerpanel).ControlinfectionwithshRNAGFPhasnoeffectonCRexpression.ForthenormalizationthesignalforGAPDH(Mr38kDa)wasused.SeealsoFigureS4.StemCellReportsjVol.8j1005–1017jApril11,20171013metastaticproperties(Raggietal.,2015).EvidencehasaccumulatedthattheseCSCsarecharacterizedbyhigherlevelsofpluripotencyfactorsincludingSOX2,OCT4,andNANOG.Basedonthis,methodshavebeendevelopedtoisolatethiscellsubpopulationasappliedinourstudy.Otherapproachestoisolate/enrichCSCsexploitspeciﬁcpropertiessuchasenhancedlevelsofdye-exclusiontransporters(ABCG2),increasedaldehydedehydrogenaseactivity(ALDH1),ortheirincreasedpropensitytogeneratespheroids(Pasdaretal.,2015).Whilethelattermethodsmightmodifythesecellstosomeextentbytheselec-tionmethod,theSOX2/OCT4reporterapproachmini-mallyperturbstheendogenousintracellularenvironment(excludingtheputativeeffectsexertedbyEGFP);itallowstheidentiﬁcationandisolationofputativeCSCsbasedontheirendogenouslyelevatedlevelsofSOX2/OCT4.HigherlevelsofSOX2inglioblastomawerelinkedwithanincreasedtumor-initiatingability(Gangemietal.,2009),inovariancarcinomaassociatedwiththestemcellstate,and,inlungcancer,CSCswererequiredforgrowthandmetastaticpotential(Xiangetal.,2011).Moreover,elevatedlevelsofOCT4andotherstemnessmarkersinMMcellsderivedfrommesosphereswereparalleledbyanincreasedtumor-initiatingcapacity(Pasdaretal.,2015).Re-porterapproachesbasedonpluripotencyfactorbindinghavebeensuccessfullyusedfortheenrichmentandidenti-ﬁcationofCSCsinbreastcancer(Tangetal.,2015;Thiagar-ajanetal.,2015)andovariancancer(Wiechertetal.,2016),thelatterusingaNANOG-basedreporter.StrongEGFPexpressioninthelentivirus-mediatedSOX2/OCT4-basedreporterapproachallowedustoisolateandcharacterizeMMcellsinvitroandfurthermoretoinvestigateindetailthepropertiesofthesecellsinvivo.Oneofthemainadvan-tagesofthereporterapproachisthepossibilityofcontinu-ouslymonitoringthesecellsovertime.ThisrevealedthatafractionofinitiallyEGFP(+)cellslosttheirgreenﬂuores-cence,likelyastheresultofadecreaseinSOX2/OCT4levelsinsufﬁcienttodriveEGFPexpression;time-lapsemoviesdemonstratedthislosstooccuroftenwithinonecelldivision.Weattributethistoadynamicshiftinthediffer-entiationstatefromEGFP(+)toEGFP( )cells,thelattercharacterizedbyamorenon-CSCphenotypeasdescribedindetailforbreastcancerCSCs(seeFigure7DinAkrapetal.,2016).Inagreement,thenewlyformedEGFP( )cellswereagainequallysusceptibletotheanti-proliferative/pro-apoptoticactionofelevatedlevelsofNF2asweretheparental-SOEGFP( )cells.ThisprecludesthelossofEGFPbeingtheresultof,e.g.,reportersilencing.ThisconclusionisalsosupportedbytheﬁndingthatthesameMMcellsconstitutivelyexpressingNLS-mCherrydidnotloseredﬂuorescenceovertime.MMareconsideredasanexample,wheretumorigenesisismostlydrivenbylossoftumorsuppressorfunctionsincludinggenessuchasNF2codingformerlin,CDKN2A,CDKN2B,orBAP1(JeanandJaurand,2015).Accord-ingly,NF2ismutatedinapproximately40%ofallhumanMM(Bianchietal.,1995)and/orcompletelyabsentbyallelicloss(Chengetal.,1999).NF2expressionlevelsarestronglycorrelatedwiththesensitivitytoinhibitorsofFAKphosphorylation(Shapiroetal.,2014).TheFAKinhib-itorVS-4718efﬁcientlyinhibitsproliferationofNF2( )MMcells,whileNF2(+)cellsareratherinsensitivetotheinhibitor.Inourstudy,wecomparedthesensitivityofEGFP(+)andEGFP( )MMcellswiththeeffectsofoverexpressionofNF2.InhumanNF2-overexpressingMM-SOcells,prolifer-ationwasalmostcompletelyblocked,whileEGFP(+)CSC-enrichedMMcellpopulationswerebarelyaffectedbyincreasedNF2levels.Thiseffectwascompletelyindepen-dentfromtheNF2statusoftheparentalcells.NF2-nega-tiveZL55cellswereequallyaffected,aswereNF2-positiveMSTO-211Hcells.TheapparentlyweakereffectinMSTO-211H-SOcellsseeninthereal-timegrowthcurves(Fig-ureS4J)isessentiallytheresultoftheinsensitivityofthesmallsubpopulationofEGFP(+)MSTO-211H-SOcellstoNF2overexpression.Adenovirus-mediatedexpressionofNF2waspreviouslyshowntoinhibitproliferationandtocauseaG1cell-cyclearrestinNF2-deﬁcienttumorcells(Xiaoetal.,2005).DetailedanalysesofNF2-overexpressingZL55-SOmostlycomprisingEGFP( )cellsrevealednotonlyaproliferation-inhibitingeffect,butconsiderablecelldeathcausedbyelevatedNF2levels.InhibitionofFAKsignalingbyVS-6063preferentiallyaffectedEGFP(+)ZL55cells,indicatingthatadirectimpairmentofFAKsignalinginCSC-enrichedZL55cellsmightbethemorepromisingstrategythanthelikelyindirecteffectonFAKsignalinginhibitionbyNF2upregulationthatmostlyaffectedtheEGFP( )ZL55cells.SincedownregulationofcalretinindecreasestheviabilityandproliferationofMMcellsinvitro(BlumandSchwaller,2013),weinvestigatedtheeffectsofdecreasingcalretininexpressioninEGFP(+)andEGFP( )cells.Interestingly,shRNACALB2-mediateddownregulationequallyaffectedbothcellpopulationswithrespecttoproliferationandcelldeath.Thus,calretininremainsaninterestingtargettoeradicatebothMMCSCsandnon-CSCs.ThelimiteddilutionassayremainsthegoldstandardfortheidentiﬁcationandcharacterizationofCSC-orTIC-enrichedcellpopulations.Herewehavechosentwoortho-topici.p.modelspresumingthattumorcellsencounteranenvironmentthatismorerelevantwithrespecttohumanMMpathology(alumencoveredbythemesothelium)thaninthemoreoftenusedsubcutaneousmodels(Pasdaretal.,2015;Shapiroetal.,2014).InthexenograftmodelusinghumanZL55cells,formationoftumornodulescoveringtheparietalaswellasthevisceralmesothelium1014StemCellReportsjVol.8j1005–1017jApril11,2017wasclearlyincreasedwheninjectingEGFP(+)cellsincomparisonwithinjection-treatedwithunsortedZL55,comprisinglessthan5%ofEGFP(+)cells.Inthephysiolog-icallymorerelevantallograftmodelusingC57BL/6JmicecharacterizedbytheirhighlycompetentimmunesystemandthepreviouslyestablishedmouseMMcelllineRN5(Blumetal.,2015),thetumor-initiatingcapacityofEGFP(+)RN5cellswasalmost20-foldhigherthanthatofEGFP( )RN5cells.Ofnote,theinitialtumorcellloadtoinducei.p.tumornoduleswithRN5cellswassigniﬁcantlyhigherthanthenumberofmouseMM87cellsthatwerein-jectedsubcutaneously(s.c.)intheNOD/SCIDmousemodel(Shapiroetal.,2014).Tosummarize,bothnormal(C57BL/6J)versuscompromised(NOD/SCID)immunesys-temcells,andorthotopicversuss.c.injectioncells,mightcontributetothehighertumorcell(RN5)loadrequiredforMMformationinvivo.IncomparisonwithCSCsfromtumorsderivedfromothertissues,thenatureofMMCSCswithrespecttoniche,interactionswiththemicroenvironment,andmostimportantlytheimmunesystemandotherproper-tiesinvivoareasyetunderexploited.WeestimatethattheEGFP-basedapproachwillallowalsotovisualizeEGFP(+)cellfateintheintacttumormicroenvironmentinthepleuralorperitonealcavities,e.g.,fordetailedlon-gitudinalstudiesinvivo.Inmostpreviousstudies,e.g.,involvementofSOX2inself-renewal(Arnoldetal.,2011)ortumor-initiatingcapability(Gangemietal.,2009)andtheroleofOCT4indedifferentiationandstemnessofcancercells(Kumaretal.,2012)hasbeeninvestigatedseparately.Finally,weproposethatthesameapproachmightbeappliedforprimary(non-trans-formed)mesothelialcells.Suchstudiesmightshedlightontheroleofnormalmesothelialstemcellsinthepro-cessoftransformationtoMM.TheinsightsintoMMCSCbiologyprovidedhereareexpectedtoberelevantinthesearchforinnovativeapproachestotargetthiscrit-icallyimportantMMcellpopulation.EXPERIMENTALPROCEDURESCellCultureandSelectionofSOX2/OCT4-ExpressingCellsMMcelllineswereculturedasdescribedabove,transducedwithlentiviruscontainingSOX2/OCT4stemnessindicatorconstructs(fordetails,seetheSupplementalExperimentalProcedures)result-ingin‘‘MM-SO’’cellsconsistingofEGFP(+)andEGFP( )subpop-ulations.Treatmentwitheither2or10mg/mLofpuromycinfor10daysledtoanenrichmentofEGFP(+)cells.Insomeexperi-ments,ZL55-SOcellswereexposedto2or10mg/mLofpuromycinfor3weeks,followedbyagrowthperiodof3weeks(10passages)withoutpuromycin.CellswerethenanalyzedbyﬂowcytometryforEGFPexpression.FlowCytometryAnalysisofEGFP(+)CellsTrypsinizedMMcellswereanalyzedbyFACSonaBDAccuriC6(BDBiosciences);detailsaredescribedintheSupplementalExper-imentalProcedures.SortingofEGFP(+)andEGFP( )cellswasperformedonaBDFACSAria(BDBiosciences)cellsorterandselectedcellswereusedforsubsequentcellcultureexperimentsinvitro.DeterminationofthemRNAExpressionofStemnessGeneLevelsbyqRT-PCRTotalRNAextractedfrom80%conﬂuentcellcultures(peqGOLDTriFast)ofpuromycin-selectedorsortedZL55-SOorRN5-SOcellswasusedforqRT-PCRfollowingthemanufacturer’sinstruc-tions(QIAGEN).qRT-PCRprimersequencesarelistedintheSup-plementalExperimentalProcedures.TreatmentofCellswithcis-Pt,5-FU,andVS-6063andDeterminationofIC50ValuesCells(500/wellforcis-Ptand5-FUexperimentsand2,000/wellforVS-6063)wereseededin96-wellplatesandgrownfor24hr.Drugswereaddedatdifferentconcentrations(fordetails,seetheSupplementalExperimentalProcedures)andtheMTTassaywasperformedat48,96,or120hrposttreatment(dependingonthedrug)todetermineIC50values.Additionally,real-timecell-prolifer-ationcurveswereacquiredwiththeIncuCyteLive-CellImagingSystem(EssenBioScience).InVivoLimitingDilutionAssayAnimalexperimentswereperformedwiththepermissionofthelocalanimalcarecommittee(CantonofFribourg,Switzerland)andaccordingtothepresentSwisslawandtheEuropeanCom-munitiesCouncilDirectiveof24November1986(86/609/EEC).MurineRN5-SOlowandRN5-SOhighcellswereresuspendedin200mLPBSandinjectedi.p.inC57Bl/6Jmice(fourmicepergroup,threedifferentconcentrations).Cells(5,000,50,000,and500,000)wereinjectedandgroupskilledinparallelafter13,11,and8weeks,respectively.Photographsweretakentoshowmacroscopictumorappearance.Organsampleswerecollected(diaphragm,spleen,liver,andperitonealwall)forhistologicalanalysis.SortedZL55-SOlowandZL55-SOhighcells(100,000/mouse)wereinjectedintoNOD/SCIDgammamice(fourtoﬁvemicepergroup).WesternBlotAssaysforCalretinin,NF2,andMesothelinProteinswereextractedfromwashedcellpellets(from70%to90%conﬂuentcultures)usingstandardRIPAbuffer(fordetails,seetheSupplementalExperimentalProcedures).Fromtheclearedsupernatant,proteins(50mg)wereseparatedon10%polyacrylamideSDSgelsandtransferredontonitrocellulosemembranes.Afterblocking,membraneswereﬁrstincubatedwithantibodiesagainstcalretinin,mesothelin,orNF2,followedbytheABCdetectionsystemusingthehorseradishperoxi-dasesubstrate(Millipore,LuminataForte);membraneswereimagedonthewesternblotreaderFluorChemESystem(BucherBiotec).StemCellReportsjVol.8j1005–1017jApril11,20171015DownregulationofCalretinininZL55-SOandZL55-SO-P2UsingLentiviral-MediatedCALB2shRNAandUpregulationofNF2Cells(500/wellin96-wellplates)weregrownfor24hrandtrans-ducedwithlentivirusshRNACALB2nos.5and7(BlumandSchwaller,2013)oranovel30UTR-targetedshRNACALB2:50-CCGGTTTAACGCGATCTTCACATTTCTCGAGAAATGTGAAGATCGCGTTAAATTTTTTG-30.MTTassayswereper-formedat120hrpostinfection.ForNF2upregulation,cellsweretransducedwithLV-NF2andgrowthcurvesweredeterminedbytheIncuCytesystem.SUPPLEMENTALINFORMATIONSupplementalInformationincludesSupplementalExperimentalProcedures,fourﬁgures,andfourmoviesandcanbefoundwiththisarticleonlineathttp://dx.doi.org/10.1016/j.stemcr.2017.02.005.ACKNOWLEDGMENTSTheauthorsthankV.Salicio,S.Eichenberger,M.Sanchez,M.Steinauer,andF.Meyenhoferfortheirexcellenttechnicalassis-tance,andT.Henzi,V.Szabolcsi,F.Filice,J.Wo¨rthmu¨ller-Rodri-guez,andV.Serre-Beinier,UniversityofGeneva,forfeedbackonthemanuscript.PL-SIN-EOS-S(4+)-EiPwasagiftfromJ.Ellis(Addgeneplasmidno.21314)andtheSORE6constructswereakindgiftofDr.L.M.Wakeﬁeld.TheprojectwassupportedbytheSwissNationalScienceFoundationSNFgrantnos.130680and139226toB.S.,SanSalvatoreFoundationandSNFSinergiagrantno.147697toE.F.-B.,M.d.P.,andB.S.Received:July18,2016Revised:February6,2017Accepted:February7,2017Published:March9,2017REFERENCESAkrap,N.,Andersson,D.,Bom,E.,Gregersson,P.,Sta˚hlberg,A.,andLandberg,G.(2016).Identiﬁcationofdistinctbreastcancerstemcellpopulationsbasedonsingle-cellanalysesoffunctionallyenrichedstemandprogenitorpools.StemCellRep.6,121–136.Anjomshoaa,A.,Nasri,S.,Humar,B.,McCall,J.L.,Chatterjee,A.,Yoon,H.-S.,McNoe,L.,Black,M.A.,andReeve,A.E.(2009).Slowproliferationasabiologicalfeatureofcolorectalcancermetastasis.Br.J.Cancer101,822–828.Arnold,K.,Sarkar,A.,Yram,M.A.,Polo,J.M.,andBronson,R.(2011).Sox2+adultstemandprogenitorcellsareimportantfortis-sueregenerationandsurvivalofmice.CellStemCell9,317–329.Bedard,P.L.,Hansen,A.R.,Ratain,M.J.,andSiu,L.L.(2013).Tumourheterogeneityintheclinic.Nature501,355–364.Bianchi,A.B.,Mitsunaga,S.I.,Cheng,J.Q.,Klein,W.M.,Jhanwar,S.C.,Seizinger,B.,Kley,N.,Klein-Szanto,A.J.,andTesta,J.R.(1995).Highfrequencyofinactivatingmutationsintheneuroﬁ-bromatosistype2gene(NF2)inprimarymalignantmesotheli-omas.Proc.Natl.Acad.Sci.USA92,10854–10858.Bille´,A.,Krug,L.M.,Woo,K.M.,Rusch,V.W.,andZauderer,M.G.(2016).Contemporaryanalysisofprognosticfactorsinpatientswithunresectablemalignantpleuralmesothelioma.J.Thorac.Oncol.11,249–255.Blum,W.,andSchwaller,B.(2013).Calretininisessentialformeso-theliomacellgrowth/survivalinvitro:apotentialnewtargetformalignantmesotheliomatherapy?Int.J.Cancer133,2077–2088.Blum,W.,Pecze,L.,Felley-Bosco,E.,Worthmu¨ller-Rodriguez,J.,Wu,L.,Vrugt,B.,dePerrot,M.,andSchwaller,B.(2015).Establish-mentofimmortalizedmurinemesothelialcellsandanovelmeso-theliomacellline.InVitroCellDev.Biol.Anim.51,714–721.Cheng,J.Q.,Lee,W.C.,Klein,M.A.,Cheng,G.Z.,Jhanwar,S.C.,andTesta,J.R.(1999).FrequentmutationsofNF2andalleliclossfromchromosomeband22q12inmalignantmesothelioma:evidenceforatwo-hitmechanismofNF2inactivation.GenesChromosomesCancer24,238–242.Cho,B.C.J.,Feld,R.,Leighl,N.,Opitz,I.,Anraku,M.,Tsao,M.-S.,Hwang,D.M.,Hope,A.,anddePerrot,M.(2014).AfeasibilitystudyevaluatingSurgeryforMesotheliomaafterRadiationTher-apy:the‘‘SMART’’approachforresectablemalignantpleuralmeso-thelioma.J.Thorac.Oncol.9,397–402.D’Angelo,R.C.,andWicha,M.S.(2010).Stemcellsinnormaldevelopmentandcancer.Prog.Mol.Biol.TranslSci.95,113–158.Frei,C.,Opitz,I.,Soltermann,A.,Fischer,B.,Moura,U.,Rehrauer,H.,Weder,W.,Stahel,R.,andFelley-Bosco,E.(2011).Pleuralmeso-theliomasidepopulationshaveaprecursorphenotype.Carcino-genesis32,1324–1332.Gangemi,R.M.R.,Griffero,F.,Marubbi,D.,Perera,M.,Capra,M.C.,Malatesta,P.,Ravetti,G.L.,Zona,G.L.,Daga,A.,andCorte,G.(2009).SOX2silencinginglioblastomatumor-initiatingcellscausesstopofproliferationandlossoftumorigenicity.StemCells27,40–48.Hirschmann-Jax,C.,Foster,A.E.,Wulf,G.G.,Nuchtern,J.G.,Jax,T.W.,Gobel,U.,Goodell,M.A.,andBrenner,M.K.(2004).Adistinct‘‘sidepopulation’’ofcellswithhighdrugefﬂuxcapacityinhumantumorcells.Proc.Natl.Acad.Sci.USA101,14228–14233.Hotta,A.,Cheung,A.Y.L.,Farra,N.,Garcha,K.,Chang,W.Y.,Pasceri,P.,Stanford,W.L.,andEllis,J.(2009).EOSlentiviralvectorselectionsystemforhumaninducedpluripotentstemcells.Nat.Protoc.4,1828–1844.Hu,Y.,andSmyth,G.K.(2009).ELDA:extremelimitingdilutionanalysisforcomparingdepletedandenrichedpopulationsinstemcellandotherassays.J.Immunol.Methods347,70–78.Jean,D.,andJaurand,M.-C.(2015).Causesandpathophysi-ologyofmalignantpleuralmesothelioma.LungCancerManag4,219–229.Klemm,F.,andJoyce,J.A.(2015).Microenvironmentalregulationoftherapeuticresponseincancer.TrendsCellBiol.25,198–213.Klonisch,T.,Wiechec,E.,Hombach-Klonisch,S.,Ande,S.R.,Wes-selborg,S.,Schulze-Osthoff,K.,andLos,M.(2008).Cancerstemcellmarkersincommoncancers–therapeuticimplications.TrendsMol.Med.14,450–460.Kumar,S.M.,Liu,S.,Lu,H.,Zhang,H.,Zhang,P.J.,Gimotty,P.A.,Guerra,M.,Guo,W.,andXu,X.(2012).Acquiredcancerstem1016StemCellReportsjVol.8j1005–1017jApril11,2017cellphenotypesthroughOct4-mediateddedifferentiation.Onco-gene31,4898–4911.Morata-Tarifa,C.,Jimenez,G.,Garcia,M.A.,Entrena,J.M.,Grinan-Lison,C.,Aguilera,M.,Picon-Ruiz,M.,andMarchal,J.A.(2016).Lowadherentcancercellsubpopulationsareenrichedintumorigenicandmetastaticepithelial-to-mesenchymaltransi-tion-inducedcancerstem-likecells.ScientiﬁcRep.6,18772.Pasdar,E.A.,Smits,M.,Stapelberg,M.,Bajzikova,M.,Stantic,M.,Goodwin,J.,Yan,B.,Stursa,J.,Kovarova,J.,Sachaphibulkij,K.,etal.(2015).Characterisationofmesothelioma-initiatingcellsandtheirsusceptibilitytoanti-canceragents.PLoSOne10,e0119549.Raggi,C.,Mousa,H.S.,Correnti,M.,Sica,A.,andInvernizzi,P.(2015).Cancerstemcellsandtumor-associatedmacrophages:aroadmapformultitargetingstrategies.Oncogene35,671–682.Shapiro,I.M.,Kolev,V.N.,Vidal,C.M.,Kadariya,Y.,Ring,J.E.,Wright,Q.,Weaver,D.T.,Menges,C.,Padval,M.,McClatchey,A.I.,etal.(2014).MerlindeﬁciencypredictsFAKinhibitorsensi-tivity:asyntheticlethalrelationship.Sci.TranslationalMed.6,237ra68.Stahel,R.A.,Felley-Bosco,E.,Opitz,I.,andWeder,W.(2009).Ma-lignantpleuralmesothelioma.FutureOncol.5,391–402.Tang,B.,Raviv,A.,Esposito,D.,Flanders,K.C.,Daniel,C.,Nghiem,B.T.,Garﬁeld,S.,Lim,L.,Mannan,P.,Robles,A.I.,etal.(2015).Aﬂexiblereportersystemfordirectobservationandisolationofcancerstemcells.StemCellRep.4,155–169.Thiagarajan,P.S.,Hitomi,M.,Hale,J.S.,Alvarado,A.G.,Otvos,B.,Sinyuk,M.,Stoltz,K.,Wiechert,A.,Mulkearns-Hubert,E.,Jarrar,A.M.,etal.(2015).Developmentofaﬂuorescentreportersystemtodelineatecancerstemcellsintriple-negativebreastcancer.StemCells33,2114–2125.Valent,P.,Bonnet,D.,DeMaria,R.,Lapidot,T.,Copland,M.,Melo,J.V.,Chomienne,C.,Ishikawa,F.,Schuringa,J.J.,Stassi,G.,etal.(2012).Perspectives.Nat.Rev.Cancer12,767–775.Vidal,S.J.,Rodriguez-Bravo,V.,Galsky,M.,Cordon-Cardo,C.,andDomingo-Domenech,J.(2013).Targetingcancerstemcellstosuppressacquiredchemotherapyresistance.Oncogene33,4451–4463.Visvader,J.E.,andLindeman,G.J.(2008).Cancerstemcellsinsolidtumours:accumulatingevidenceandunresolvedquestions.Nat.Rev.Cancer8,755–768.Wiechert,A.,Saygin,C.,Thiagarajan,P.S.,Rao,V.S.,Hale,J.S.,Gupta,N.,Hitomi,M.,Nagaraj,A.B.,DiFeo,A.,Lathia,J.D.,andReizes,O.(2016).Cisplatininducesstemnessinovariancancer.Oncotarget7,30511–30522.Xiang,R.,Liao,D.,Cheng,T.,Zhou,H.,Shi,Q.,Chuang,T.S.,Mar-kowitz,D.,Reisfeld,R.A.,andLuo,Y.(2011).DownregulationoftranscriptionfactorSOX2incancerstemcellssuppressesgrowthandmetastasisoflungcancer.Br.J.Cancer104,1410–1417.Xiao,G.-H.,Gallagher,R.,Shetler,J.,Skele,K.,Altomare,D.A.,Pestell,R.G.,Jhanwar,S.,andTesta,J.R.(2005).TheNF2tumorsuppressorgeneproduct,merlin,inhibitscellproliferationandcellcycleprogressionbyrepressingcyclinD1expression.Mol.CellBiol.25,2384–2394.Xu,J.,Kadariya,Y.,Cheung,M.,Pei,J.,Talarchek,J.,Sementino,E.,Tan,Y.,Menges,C.W.,Cai,K.Q.,Litwin,S.,etal.(2014).GermlinemutationofBap1acceleratesdevelopmentofasbestos-inducedmalignantmesothelioma.CancerRes.74,4388–4397.StemCellReportsjVol.8j1005–1017jApril11,20171017